USA flag logo/image

An Official Website of the United States Government

Time-reversal acoustic device for enhanced drug delivery for brain gliomas

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
94063
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
NS065524
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ARTANN LABORATORIES, INC.
1459 LOWER FERRY RD TRENTON, NJ -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Time-reversal acoustic device for enhanced drug delivery for brain gliomas
Agency: HHS
Contract: 1R43NS065524-01
Award Amount: $718,337.00
 

Abstract:

DESCRIPTION (provided by applicant): The main objective of this SBIR Phase I application is to demonstrate the feasibility of a novel technology for focusing ultrasound based on time-reversal acoustics (TRA) principle to improve the effectiveness of convec tion-enhanced delivery (CED) of drugs to the brain. CED is a promising method of drug delivery to the brain for the treatment of several disorders. CED bypasses the blood-brain barrier by infusing compounds through a needle or microcatheter directly into b rain parenchyma or brain tumor. The infusion establishes a pressure gradient in the tissue that drives a flow of infusate away from the needle. Preclinical and clinical studies suggest that the outcome of the therapy depends strongly on the diffusion rate and extent of penetration of the drug into the brain. It has been shown that dramatic increase of the penetration depth can be obtained by combining the CED with focused ultrasound. In vivo focusing of ultrasound in the brain is complicated because of the irregular shape of the skull which distorts the acoustic wave front. TRA principles allow for compensation of any kind of acoustic wave front distortion and provide efficient focusing in composite heterogeneous media, especially within closed reverberating cavities, such as in the skull. A miniature piezotransducer attached to tip of the needle used for injecting the drug, acts as a beacon necessary for accurate focusing of ultrasound to exactly the region where the drug is injected. Highly accurate focusin g of ultrasound using the TRA principle minimizes the exposure of healthy tissue to high intensity ultrasound. The goal of the proposed research is to develop an acoustic device for ultrasound-enhanced therapy for several brain disorders that can ultimatel y be used in a clinical setting. Optimal ultrasound exposure parameters will be determined in order to achieve the maximum enhancement of the penetration of the infusate with minimum damage to healthy cells. The performance of the TRA focusing system and e nhancement of infusate penetration will be tested in tissue mimicking phantoms and in animal experiments in vivo. PUBLIC HEALTH RELEVANCE: The long-term goal of this project is to develop, build and bring to the market an acoustic system for highly accurat e focusing ultrasound to selected sites in the brain to improve convection enhanced drug delivery, which is a promising new therapy for the treatment of brain disorders, including brain tumors. The technology developed in the project will improve the effic acy of the therapy, which eventually should lead to better outcomes in patients suffering from a variety of brain malignancies.

Principal Investigator:

Armen Sarvazyan
6093330710
ARMEN@ARTANNLABS.COM

Business Contact:

Armen Sarvaxyan
artann@artannlabs.com
Small Business Information at Submission:

ARTANN LABORATORIES, INC.
ARTANN LABORATORIES, INC. 1459 LOWER FERRY RD TRENTON, NJ 08618

EIN/Tax ID: 223503679
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No